'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis

Current Opinion in Obstetrics and Gynecology

Volumn 23, Issue 1, 2011, Pages 19-23

  Liu, Naifu ^a   Wang, Xingwu ^a   Sheng, Xiugui ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

breast cancer; endometrial cancer; epithelial ovarian cancer; prognosis; targeted therapy; triple negative phenotype

Indexed keywords

ANDROGEN RECEPTOR; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CHECKPOINT KINASE 1; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; K RAS PROTEIN; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; SUNITINIB; TUMOR MARKER;

AFRICAN AMERICAN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STEM CELL; DISEASE MARKER; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER; TRIPLE NEGATIVE EPITHELIAL OVARIAN CANCER; TRIPLE NEGATIVE EPITHELIAL OVARY CANCER;

BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 78651421517     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32834252f5     Document Type: Article

References (37)

1. Nakayama K, Takebayashi Y, Nakayama S, et al. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 2003; 192:227-235. (Pubitemid 36369277)
2. Lee P, Rosen DG, Zhu C, et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005; 96:671-677. (Pubitemid 40255486)
3. Garcra-Velasco A, Mendiola C, Sanchez-Muñoz A, et al. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol 2008; 10:367-371.
4. Ferrandina G, Ranelletti FO, Lauriola L, et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 2002; 85:305-310. (Pubitemid 34522990)
5. Chacón R, Costanzo M. Triple-negative breast cancer. Breast Cancer Res 2010; 12 (Suppl 2):S3.
6. Liu N, Wang X, Sheng X. The clinicopathological characteristics of triplenegative epithelial ovarian cancer. J Clin Pathol 2010; 63:240-243.
7. Kothari R, Morrison C, Richardson D, et al. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol 2010; 118:172-175.
8. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institutes Surveillance, Epidemiology, and End Results database. Cancer 2007; 110:876-884. (Pubitemid 47257667)
9. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109:25-32. (Pubitemid 46120191)
10. Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008; 8:307.
11. Jones C, Mackay A, Grigoriadis A, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004; 64: 3037-3045. (Pubitemid 38581402)
12. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the triple-negative phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116:317-328.
13. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367-5374. (Pubitemid 39100473)
14. Carey L, Rugo H, Marcom S. TBCRC 001: EGFR inhibition with cetuximab added to carboplatinum in metastatic TNBC (basal like). J Clin Oncol 2008; (Suppl 15):abstract 1009.
15. Bosch A, Eroles P, Zaragoza R, et al. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010; 36:206-215.
16. Berrada N, Delaloge S, André F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol 2010; 21 (Suppl 7):vii30-vii35.
17. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15:441-451.
18. Marty B, Maire V, Gravier E, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008; 10:R101.
19. Lee YK, Park NH. Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecol Oncol 2009; 112:475-480.
20. Trinh XB, van Dam PA, Dirix LY, et al. The rationale for mTOR inhibition in epithelial ovarian cancer. Expert Opin Investig Drugs 2009; 18:1885-1891.
21. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 2010; 29:585-590.
22. Nodin B, Zendehrokh N, Brändstedt J, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res 2010; 3:14.
23. Ludwig AH, Murawska M, Panek G, et al. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer 2009; 16:1005-1016.
24. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20:2310-2318. (Pubitemid 34441658)
25. Tutt A, Robson M,Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-244.
26. OShaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009; (18 Suppl):abstract 3.
27. Brustmann H. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol 2007; 26:147-153. (Pubitemid 46573210)
28. Fong PC, Yap TA, Boss DS, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28:2512-2519.
29. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376:245-251.
30. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26:1810-1816.
31. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
32. Smerdel MP, Waldstram M, Brandslund I, et al. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19:578-584.
33. Han ES, Monk BJ. Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 2007; 7:1339-2145.
34. Park SY, Lee HE, Li H, et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16:876-887.
35. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29:2013-2023.
36. Bouchalova K, Cizkova M, Cwiertka K, et al. Triple negative breast cancer: current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153:13-17.
37. Rodriguez-Pinilla SM, Jones RL, Lambros MB, et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol 2007; 60:1017-1023. (Pubitemid 47441935)